A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis
Latest Information Update: 05 Jan 2026
At a glance
- Drugs VC 005 (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
Most Recent Events
- 02 Jan 2026 Status changed from not yet recruiting to recruiting.
- 19 Sep 2025 New trial record